Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
{{output}}
Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may l... ...